Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age

Vaccine

Volumn 31, Issue 46, 2013, Pages 5300-5305

  Heyward, William L ^a   Kyle, Michael ^b   Blumenau, Joseph ^c   Davis, Matthew ^d   Reisinger, Keith ^e   Kabongo, Martin L ^f   Bennett, Sean ^a   Janssen, Robert S ^a   Namini, Hamid ^a   Martin, J Tyler ^a  

^a Dynavax Technologies Corporation   (United States)

^b RADIANT RESEARCH   (United States)

^c Research Across America   (United States)

^d Rochester Clinical Research   (United States)

^e Primary Physicians Research   (United States)

^f Accelovance Inc   (United States)

Author keywords

Hepatitis B vaccine; Randomized trial; Toll like receptor 9 agonist

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B SURFACE ANTIGEN 1018; HEPATITIS B SURFACE ANTIGEN ENG; HEPATITIS B VACCINE; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEART FAILURE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SINGLE BLIND PROCEDURE; SKIN REDNESS; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VACCINATION; VITILIGO;

HEPATITIS B VACCINE; RANDOMIZED TRIAL; TOLL-LIKE RECEPTOR 9 AGONIST;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; VACCINATION;

EID: 84886086527     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.05.068     Document Type: Article

References (27)

1. Fact sheet no. 204: hepatitis B 2012, World Health Organization, http://www.who.int/mediacentre/factsheets/fs204/en/print.html (Retrieved 11.12.12).
2. Disease burden from viral hepatitis A, B, and C in the United States 2011, Centers for Disease Control and Prevention, http://www.cdc.gov/hepatitis/hbv/statisticshbv.htm.
3. Weber D.J., Rutala W.A., Samsa G.P., Santimaw J.E., Lemon S.M. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985, 254(22):3187-3189.
4. Westmoreland D., Player V., Heap D.C., Hammond A. Immunization against hepatitis B - what can we expect? Results of a survey of antibody response to immunization in persons 'at risk' of occupational exposure to hepatitis B. Epidemiol Infect 1990, 104(3):499-509.
5. Wismans P.J., van Hattum J., de Gast G.C., Bouter K.P., Diepersloot R.J.A., Maikoe T., et al. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls?. J Med Virol 1991, 35(3):216-222.
6. Wolters B., Junge U., Dziuba S., Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons?. Vaccine 2003, 21(25-26):3623-3628.
7. Roome A.J., Walsh S.J., Cartter M.L., Hadler J.L. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993, 270(24):2931-2934.
8. Wood R.C., MacDonald K.L., White K.E., Hedberg C.W., Hanson M., Osterholm M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993, 270(24):2935-2939.
9. Bock H.L., Kruppenbacher J., Sanger R., Hobel W., Clemens R., Jilg W., et al. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 1996, 156(19):2226-2231.
10. Douvin C., Simon D., Charles M.-A., Deforges L., Bierling P., Lehner V., et al. Hepatitis B vaccination in diabetic patients? Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabet Care 1997, 20(2):148-151.
11. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998 Jul, 15(1):1-8.
12. Rendi-Wagner P., Kundi M., Stemberger H., Wiedermann G., Holzmann H., Hofer M., et al. Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. Vaccine 2001, 19(February (15-16)):2055-2060.
13. Fisman D.N., Agrawal D., Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis?. Clin Infect Dis 2002, 35(11):1368-1375.
14. Wolters B., Junge U., Dziuba S., Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 2003, 21(September (25-26)):3623-3628.
15. Van der Wielen M., Van Damme P., Chlibek R., Smetana J., von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine 2006, 24(June (26)):5509-5515.
16. Tohme R.A., Awosika-Olumo D., Nielsen C., Khuwaja S., Scott J., Xing J., et al. Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities. Vaccine 2011, 29:9316-9320.
17. Halperin S.A., Ward B., Cooper C., Predy G., Diaz-Mitoma F., Dionne M., et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine 2012, 30(March (15)):2556-2563.
18. Halperin S.A., McNeil S., Langley J.M., Smith B., MacKinnon-Cameron D., McCall-Sani R., et al. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 2012, 30(August (36)):5445-5448.
19. Sablan B.P., Kim D.J., Barzaga N.G., Chow W.C., Cho M., Ahn S.H., et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012, 30(March (16)):2689-2696.
20. Recommendation of the immunization practices advisory committee (ACIP) inactivated hepatitis B virus vaccine. MMWR 1982, 31:24. Centers for Disease Control.
21. Francis D.P., Hadler S.C., Thompson S.E., Maynard J.E., Ostrow D.G., Altman N., et al. The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. Ann Intern Med 1982, 97(3):362-366.
22. Szmuness W., Stevens C.E., Zang E.A., Harley E.J., Taylor P.E., Kellner A., et al. Hepatitis B vaccine: a controlled clinical trial in homosexual men. Viral Hepatitis 1982, 467-486.
23. Sensitivity of the test for antibody to hepatitis B surface antigen - United States. MMWR 1993, 42(36):707-710. Centers for Disease Control.
24. Jack A.D., Hall A.J., Maine N., Mendy M., Whittle H.C. What level of hepatitis B antibody is protective?. J Infect Dis 1999, 179(2):489-492.
25. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., et al. Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005, 54(December (RR-16)):1-31.
26. Nelson J.C., Bittner R.C., Bounds L., Zhao S., Baggs J., Donahue J.G., et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health 2009, 99(October (Suppl. 2)):S389-S397.
27. Clopper C.J., Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26:404-413.